601607 上海医药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入70,762,5160.87%275,250,935260,295,089231,981,300215,824,259
减:营业总成本68,666,6351.14%267,676,307253,008,864224,907,251209,641,475
    其中:营业成本63,506,1642.22%244,619,261228,966,947201,494,923187,281,149
               财务费用374,7180.08%1,480,9121,485,7581,313,1921,245,369
               资产减值损失33,52323.13%(614,374)(561,277)(331,471)(140,441)
公允价值变动收益37,803-27.65%203,854404,731218,738(206,004)
投资收益171,7383.18%380,427(68,123)533,1171,811,394
    其中:对联营企业和合营企业的投资收益215,8296.17%521,909129,329526,743789,596
营业利润2,146,390-11.11%8,140,7137,667,2359,014,6508,205,486
利润总额2,152,717-10.92%8,020,0077,054,2978,808,3538,143,815
减:所得税费用512,524-7.00%2,149,9951,887,7261,816,3391,869,245
净利润1,640,193-12.08%5,870,0115,166,5706,992,0156,274,569
减:非控股权益307,123-5.00%1,317,4831,398,5711,374,8631,181,102
股东净利润1,333,070-13.56%4,552,5283,768,0005,617,1525,093,467

市场价值指针
每股收益 (元) *0.360-14.29%1.2301.0201.6101.790
每股派息 (元) *----0.3700.4100.6100.420
每股净资产 (元) *19.6884.07%19.33018.50018.13717.367
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容